Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành hóa học dành cho các bạn yêu hóa học tham khảo đề tài: Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer | Simonetti et al. Journal of Translational Medicine 2010 8 135 http content 8 1 135 TRANSLATIONAL MEDICINE RESEARCH Open Access Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer 1 1 2 2 1 1 Sara Simonetti Miguel Angel Molina Cristina Queralt Itziar de Aguirre Clara Mayo Jordi Bertran-Alamillo Iz xr-zA I-X X Í z-x r o s r Lx Z x 73 I z r- z I I I I r- L X 7 X I I r r 1l x 4 I I I z x I z I i x-vx z-x v-x z-x-75 I rz-x r I r I 6 I z r i I-Z x ri 1 José Javier sancnez Jose Luis Gonzalez-Larriba Ulpiano Jimenez Dolores Isla leresa Moran Santiago Viteri z I z 7 z I 8 9 1 110 Carlos Camps Rosario Garcia-Campelo Bartomeu Massuti Susana Benlloch Santiago Ramon y Cajal Miquel Taron1 2 Rafael Rosell1 2 Abstract Background Immunohistochemistry IHC with mutation-specific antibodies may be an ancillary method of detecting EGFR mutations in lung cancer patients. Methods EGFR mutation status was analyzed by DNA assays and compared with IHC results in five non-small-cell lung cancer NSCLC cell lines and tumor samples from 78 stage IV NSCLC patients. Results IHC correctly identified del 19 in the H1650 and PC9 cell lines L858R in H1975 and wild-type EGFR in H460 and A549 as well as wild-type EGFR in tumor samples from 22 patients. IHC with the mAb against EGFR with del 19 was highly positive for the protein in all 17 patients with a 15-bp ELREA deletion in exon 19 whereas in patients with other deletions IHC was weakly positive in 3 cases and negative in 9 cases. IHC with the mAb against the L858R mutation showed high positivity for the protein in 25 27 93 patients with exon 21 EGFR mutations all with L858R but did not identify the L861Q mutation in the remaining two patients. Conclusions IHC with mutation-specific mAbs against EGFR is a promising method for detecting EGFR mutations in NSCLC patients. However these mAbs should be validated with additional studies to clarify their possible role in .
